{
    "organizations": [],
    "uuid": "48469f563a3162de40d2289f0c76cc4d71a3395e",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-karo-pharma-board-of-directors-res/brief-karo-pharma-board-of-directors-resolves-on-fully-guaranteed-rights-issue-idUSFWN1RH047",
    "ord_in_thread": 0,
    "title": "BRIEF-Karo Pharma: Board Of Directors Resolves On Fully Guaranteed Rights Issue",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 4 (Reuters) - KARO PHARMA AB:\n* THE BOARD OF DIRECTORS OF KARO PHARMA HAS RESOLVED ON A FULLY GUARANTEED RIGHTS ISSUE SUBJECT TO APPROVAL BY THE ANNUAL GENERAL MEETING\n* IS EXPECTED TO RECEIVE ISSUE PROCEEDS AMOUNTING TO ABOUT SEK 1.3 BILLION BEFORE TRANSACTION COSTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-04T18:45:00.000+03:00",
    "crawled": "2018-04-05T17:12:20.062+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "karo",
        "pharma",
        "ab",
        "board",
        "director",
        "karo",
        "pharma",
        "resolved",
        "fully",
        "guaranteed",
        "right",
        "issue",
        "subject",
        "approval",
        "annual",
        "general",
        "meeting",
        "expected",
        "receive",
        "issue",
        "proceeds",
        "amounting",
        "sek",
        "billion",
        "transaction",
        "cost",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}